Research programme: bryostatin analogues - GPC Biotech

Drug Profile

Research programme: bryostatin analogues - GPC Biotech

Alternative Names: Bryologs research programme - GPC Biotech; Bryostatin analogues research programme - GPC Biotech

Latest Information Update: 11 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer GPC Biotech Inc
  • Class
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 Mar 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 31 Jul 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top